Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system
BackgroundLecanemab and donanemab are anti-amyloid-β (Aβ) monoclonal antibodies recently approved for the treatment of Alzheimer’s disease (AD). Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting profiles remain insufficiently characterized and...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2026-06-01
|
| Serie: | Frontiers in Pharmacology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1868789/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|